Johnson Paul Harold 4

What Happened

• Paul H. Johnson, a director of Lifecore Biomedical, Inc. (LFCR), received a grant of 25,907 restricted stock units (RSUs) on June 4, 2026. The grant is reported as an award (Form 4 transaction code A); no per-share price or aggregate dollar amount is reported for the grant.
• These RSUs convert into Lifecore common stock on a 1-for-1 basis when they vest. This is a compensated award (not an open-market purchase or sale), so it is neither an explicit bullish nor bearish trading signal by itself.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-05 (timely filing).
• Shares/units granted: 25,907 restricted stock units (RSUs); price: N/A; aggregate dollar amount not reported.
• Vesting: RSUs vest on the earlier of June 4, 2027 or the date of the Company’s 2027 annual meeting of stockholders, provided that meeting occurs at least 50 weeks after June 4, 2026.
• Conversion: RSUs convert 1-for-1 into common shares upon vesting (footnote).
• Shares owned after transaction: not specified in the filing.

Context

• RSU grants are common for directors and employees as compensation and represent future stock delivery if vesting conditions are met; they do not reflect an immediate purchase or sale of shares.
• For shareholders, note this increases potential future share issuance if the RSUs vest and are settled in stock.